limb and CNS expressed 1Genealiases: C5orf11 · Lft
Q-omics provides the consensus-scored LIX1 profile across patient tissues and cancer cell-line models. LIX1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LIX1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LIX1 RNA expression shows 10,142 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KICH, and TGCT as cancer lineages where LIX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIX1 survival associations across molecular data types. LIX1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIX1 RNA expression–survival associations across cancer types. High LIX1 expression shows unfavorable associations in MESO, ACC, UCEC, SCLC and READ, but favorable associations in KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for LIX1 RNA expression.
This table summarizes LIX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LIX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIX1 shows lower tumor expression in KICH, THCA, KIRC, KIRP and COAD and higher tumor expression in BRCA. The KICH box plot shows higher LIX1 RNA expression in normal versus tumor tissue (log2 FC = −4.035, t-test p < 0.001).
This table shows molecular features associated with LIX1 in patient tissues and cancer cell lines. In patient samples, LIX1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LIX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and OVARY.
